OncoMatch/Clinical Trials/NCT06790082

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma

Is NCT06790082 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies [68Ga]Ga-FAPI-46 PET/CT for pleural mesothelioma.

Treatment: [68Ga]Ga-FAPI-46 PET/CT — Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT). The diagnostic accuracy will be determined with histopathology as reference standard. For patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET/CT and an additional FDG PET/CT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET/CT in response evaluation will be investigated. All study specific analyzes will be blinded and will not influence the patient management / treatment.